Dr Imran Patanwala is a highly distinguished Consultant Gastroenterologist and Hepatologist whose career is defined by a rigorous academic foundation and leadership within the UK’s most prominent medical institutions. Having been awarded the Pfizer Gold Medal for academic excellence during his initial training in India, he subsequently refined his expertise through specialist training in the North East of England. His tenure at the renowned Freeman Hospital Liver Transplant Unit and his selection for the prestigious Hesperis Course in Organ Transplantation underscore a level of expertise that is globally recognised. This formidable clinical background is further bolstered by his leadership as the Head of Clinical Hepatology at Manchester University Hospitals NHS Foundation Trust between 2022 and 2025, marking him as a significant figure in regional healthcare strategy and specialist delivery.
As a clinician, Dr Patanwala offers an exhaustive range of diagnostic and therapeutic services, with a particular focus on complex liver pathology. His MD research from the University of Newcastle upon Tyne into portal hypertension and autoimmune liver disease informs a practice that is deeply rooted in cutting-edge science. He is an expert in the management of cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and liver fibrosis, while also maintaining a high-calibre endoscopy practice. His accreditation in bowel cancer screening and his role in specialist regional multidisciplinary teams for haematology-related liver conditions demonstrate a versatile and integrated approach to internal medicine, ensuring that even the most intricate systemic cases receive nuanced care.
Beyond the clinic, Dr Patanwala is a prolific contributor to the advancement of hepatology through his extensive research and academic involvement. His work, published in numerous peer-reviewed journals, directly influences modern medical practice, particularly his contributions to national clinical guidelines regarding the pharmacological management of fatty liver disease. Despite these high-level academic and leadership commitments, his approach to patient care remains grounded in clarity and empathy. He prioritises evidence-based management and transparent communication, ensuring that patients are not merely recipients of treatment, but are fully informed and supported partners throughout their diagnostic and therapeutic journeys.
